Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy - PubMed (original) (raw)

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy

S C Grant et al. Cancer Chemother Pharmacol. 1993.

Abstract

Dazopride, a substituted benzamide structurally related to metoclopramide, is a potent gastric prokinetic agent that prevents cisplatin-induced emesis in animals. Unlike metoclopramide, dazopride has no effect on dopamine receptors and therefore should not produce extrapyramidal side effects. In this dose-ranging trial, 23 patients with cancer receiving chemotherapy known to produce nausea and vomiting received three i.v. infusions of dazopride every 2 h beginning 30 min before the chemotherapy. Seven dose levels were explored ranging from 0.5 to 4.0 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, visual disturbances, and headaches. All side effects were transient and were not dose-related. Antiemetic effects were observed. Dazopride can be safely given on this schedule at doses of up to 4.0 mg/kg to patients receiving chemotherapy. On the basis of the results of this trial, further studies of this agent are warranted.

PubMed Disclaimer

Similar articles

• Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
  Baltzer L, Kris MG, Tyson LB, Rigas JR, Vreeland F, Pisters KM. Baltzer L, et al. Cancer. 1993 Nov 1;72(9):2695-9. doi: 10.1002/1097-0142(19931101)72:9<2695::aid-cncr2820720928>3.0.co;2-s. Cancer. 1993. PMID: 8402492 Clinical Trial.
• Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
  Kris MG, Gralla RJ, Clark RA, Tyson LB. Kris MG, et al. J Clin Oncol. 1988 Apr;6(4):659-62. doi: 10.1200/JCO.1988.6.4.659. J Clin Oncol. 1988. PMID: 2965755
• Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility.
  Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, Johnson DN, Sancilio LF, Ward JW. Alphin RS, et al. Dig Dis Sci. 1986 May;31(5):524-9. doi: 10.1007/BF01320319. Dig Dis Sci. 1986. PMID: 3698769
• Combination antiemetics for cisplatin chemotherapy.
  Sridhar KS, Donnelly E. Sridhar KS, et al. Cancer. 1988 Apr 15;61(8):1508-17. doi: 10.1002/1097-0142(19880415)61:8<1508::aid-cncr2820610806>3.0.co;2-h. Cancer. 1988. PMID: 3280112 Review.
• Comparative activity of antiemetic drugs.
  Jordan K, Schmoll HJ, Aapro MS. Jordan K, et al. Crit Rev Oncol Hematol. 2007 Feb;61(2):162-75. doi: 10.1016/j.critrevonc.2006.08.003. Crit Rev Oncol Hematol. 2007. PMID: 17208005 Review.

Cited by

• Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
  Shen DW, Pouliot LM, Hall MD, Gottesman MM. Shen DW, et al. Pharmacol Rev. 2012 Jul;64(3):706-21. doi: 10.1124/pr.111.005637. Epub 2012 Jun 1. Pharmacol Rev. 2012. PMID: 22659329 Free PMC article. Review.
• Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies.
  Torta R, Berra C, Binaschi L, Borio R. Torta R, et al. Support Care Cancer. 2007 May;15(5):539-46. doi: 10.1007/s00520-006-0194-7. Epub 2007 Feb 14. Support Care Cancer. 2007. PMID: 17406919

References

1. 1. N Engl J Med. 1983 Aug 18;309(7):433-4 - PubMed
2. 1. Dig Dis Sci. 1986 May;31(5):524-9 - PubMed
3. 1. J Clin Oncol. 1991 Apr;9(4):675-8 - PubMed
4. 1. J Clin Oncol. 1988 Apr;6(4):659-62 - PubMed
5. 1. J Natl Cancer Inst. 1989 Jan 4;81(1):42-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information